StreetInsider.com News Articles

Braveheart Bio raises $439.9M in upsized Nasdaq IPO

Fri, 07 Aug 2026 16:05:10 -0400

Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company, closed its initial public offering of 24,437,500 shares of common stock at $18.00 per share, according to a press release statement.

The total share count includes the full exercise by underwriters of an option to purchase 3,187,500 additional shares. All shares were offered by Braveheart Bio. Gross proceeds from the offering totaled $439.9 million before deducting underwriting discounts, commissions, and other offering expenses.

The shares began trading on the Nasdaq Global Market on Aug. 6, 2026, under the ticker symbol "BRVE."

Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel, and Cantor served as

Braveheart Bio raises $439.9M in upsized Nasdaq IPO

Fri, 07 Aug 2026 16:05:10 -0400

The shares began trading on the Nasdaq Global Market on Aug. 6, 2026, under the ticker symbol "BRVE."

Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel, and Cantor served as

Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Fri, 07 Aug 2026 16:05:00 -0400

SAN FRANCISCO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced the closing of its upsized initial public offering of an aggregate of 24,437,500 shares of its common stock at an initial public offering price of $18.00 per share, including the full exercise by the underwriters of their option to purchase 3,187,500 additional shares. All shares of common stock were offered by Braveheart Bio. The shares began trading on the Nasdaq Global Market on August 6, 2026 under

Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Fri, 07 Aug 2026 16:05:00 -0400

Braveheart Bio shares surge 68% in New York trading debut

Thu, 06 Aug 2026 13:08:39 -0400

Investing.com -- Braveheart Bio Inc. shares rose 68% in the company's first day of trading on Thursday after the clinical-stage biopharmaceutical firm completed a $382.5 million initial public offering in the United States.

The stock opened at $30.20 per share in New York, climbing above the IPO price of $18. The company's market value reached $2.13 billion based on outstanding shares.

Braveheart Bio, established in 2024, is working on BHB-1893, its primary drug candidate designed to treat hypertrophic cardiomyopathy, an inherited heart condition that impairs the heart's ability to pump blood. The company obtained licensing rights for the asset from Jiangsu Hengrui

Braveheart Bio prices IPO at $18 per share, raises $382.5M

Wed, 05 Aug 2026 22:33:40 -0400

Braveheart Bio, Inc. (NASDAQ: BRVE), a clinical-stage biopharmaceutical company focused on cardiovascular disease treatments, has priced its initial public offering of 21,250,000 shares of common stock at $18.00 per share, according to a press release.

The gross proceeds from the offering are expected to total $382.5 million, before deducting underwriting discounts, commissions, and other expenses. The company has also granted underwriters a 30-day option to purchase up to an additional 3,187,500 shares at the IPO price.